tivozanib Articles

FDA advisory votes against AVEO and Astellas' cancer drug tivozanib

3 May 2013

Advantages of Tivopath over currently used kidney cancer therapies seen by thought leaders

27 March 2013

AVEO/Astellas' kidney cancer drug tivozanib fails to beat Nexavar

14 February 2013

AVEO and Astellas file NDA for tivozanib in kidney cancer

2 October 2012

AVEO and Astellas’ tivozanib beats sorafenib in Ph III TIVO-1 trial

4 January 2012

Aveo set to earn more than $1.3 billion in licensing deal with Astellas for cancer drug tivozanib

17 February 2011

Showing 1-6 of 6 articles

Go to beginning

Previous

1

Next

Go to end